BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9834240)

  • 1. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
    Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
    Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
    Rapozzi V; Cogoi S; Xodo LE
    Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
    Zhu XS; Lin ZY; Du J; Cao GX; Liu G
    Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
    Martiat P; Lewalle P; Taj AS; Philippe M; Larondelle Y; Vaerman JL; Wildmann C; Goldman JM; Michaux JL
    Blood; 1993 Jan; 81(2):502-9. PubMed ID: 8422466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
    Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
    Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells.
    Cirino NM; Li G; Xiao W; Torrence PF; Silverman RH
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1937-42. PubMed ID: 9050883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL; Lewalle P; Martiat P
    Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
    Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Verfaillie CM
    Blood; 1998 May; 91(9):3414-22. PubMed ID: 9558400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of selective modifications to a 2',5'-oligoadenylate-3',5'-deoxyribonucleotide antisense chimera with affinity for the target nucleic acid and with ability to activate RNase L.
    Xiao W; Li G; Maitra RK; Maran A; Silverman RH; Torrence PF
    J Med Chem; 1997 Apr; 40(8):1195-200. PubMed ID: 9111293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells.
    Hoshiko T; Kubota Y; Akisawa T; Watanabe T; Tanigawara K; Yano J; Kimura S
    Invest New Drugs; 2020 Aug; 38(4):1012-1019. PubMed ID: 31650445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.
    Pigneux A; Mahon FX; Jazwiec B; Pigeonnier V; Ripoche J; Reiffers J
    Leuk Lymphoma; 2000 Feb; 36(5-6):569-78. PubMed ID: 10784402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.